SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin launches Imatinib Mesylate Tablets

09 Jul 2019 Evaluate

Lupin has launched Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base). Lupin’s alliance partner Natco had received an approval from the United States Food and Drug Administration (USFDA) earlier. 

Lupin’s Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base), is the generic version of Novartis Pharmaceuticals Corporation’s (Novartis) Gleevec Tablets, 100 mg and 400 mg.

Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base), had annual sales of approximately $548 million in the US (IQVIA MAT May 2019). 

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2311.75 -16.85 (-0.72%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×